Positive Outlook for Roivant Sciences Driven by Brepocitinib’s Phase 3 Potential and Undervalued Stock

Samantha Semenkow, an analyst from Citi, has initiated a new Buy rating on Roivant Sciences (ROIV).

Samantha Semenkow’s rating is based on several compelling factors. One of the primary reasons is the anticipated positive outcome of the Phase 3 VALOR study for brepocitinib, a JAK1/TYK2 inhibitor, in treating dermatomyositis (DM). Although there is a lack of Phase 2 proof-of-concept data, the extensive literature of investigator-sponsored trials and case studies suggests a promising efficacy signal for JAK1 inhibition. The dual targeting mechanism of JAK1 and TYK2 is expected to enhance the treatment’s effectiveness, and the mandatory steroid taper in the study could help reduce placebo effects, potentially leading to a favorable readout.
Samantha also notes that Roivant Sciences’ current stock valuation does not fully reflect the potential value of brepocitinib, indicating room for significant upside if the Phase 3 results are positive. Additionally, IMVT-1402, another asset in Roivant’s portfolio, is seen as a potential best-in-class FcRN inhibitor with blockbuster potential across various autoimmune diseases, although its development timeline is longer. The combination of these factors, along with the potential for future valuation growth, supports the Buy rating for Roivant Sciences.

Based on the recent corporate insider activity of 116 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROIV in relation to earlier this year.